Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by bringon10baggeron Jun 06, 2020 12:42pm

262 Views

Post# 31120164

RE:RE:RE:RE:RE:RE:What should the share price have been with these 2b results?

Nice find mugs.....either Dan will have regional deals to fund P3, interesting of him to mention China-huge market opportunity, will come with sigificant bucks or a similar deal with big pharma as mentioned here......I'm sure ATE mgmt is still shaking/scratching their heads of where the sp is.

MUGMODs wrote: hard to find comparables and it’s all a guessing game from here - as to what kind of deals could be had - I’d say we have lots of interest and the money to be made after P3 is considerable.

We are derisked but I’d assume this recent immunotheropy deal is far from certain - with many competitors trying to come to market. Obviously had to search far and wide to strike a deal with a larger entity ... not us. IMO

https://www.newswire.ca/news-releases/oncoquest-signs-a-definitive-agreement-to-sell-drug-portfolio-to-dual-industrial-for-u-s-300-million-and-commitment-to-fund-the-oregovomab-phase-3-clinical-trial-in-frontline-ovarian-cancer-897102798.html